Ipsen

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:20 2024-04-15 am EDT			5-day change	1st Jan Change
108.4 ^EUR	-0.91%		+0.09%	+0.46%

Apr. 15	Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	CF
Apr. 02	Ipsen: worldwide licensing agreement with Sutro Biopharma	CF

IPSEN: Disclosure of Transactions in Own Shares Between 17/08/2020 and 21/08/2020

August 25, 2020 at 12:01 pm EDT

Regulatory News:

Aggregated presentation by day and market

Issuer name	Issuer identification code	Transaction date	Identification code of the financial instrument	Daily total volume (in number of shares)	Daily weighted average price of shares acquired	Platform
IPSEN	549300M6SGDPB4Z94P11	17/08/2020	FR0010259150	0	0	XPAR
IPSEN	549300M6SGDPB4Z94P11	18/08/2020	FR0010259150	2,507	86,82	XPAR
IPSEN	549300M6SGDPB4Z94P11	19/08/2020	FR0010259150	0	0	XPAR
IPSEN	549300M6SGDPB4Z94P11	20/08/2020	FR0010259150	0	0	XPAR
IPSEN	549300M6SGDPB4Z94P11	21/08/2020	FR0010259150	6,146	86,12	XPAR
IPSEN	549300M6SGDPB4Z94P11	21/08/2020	FR0010259150	1,646	86,12	CHIX
IPSEN	549300M6SGDPB4Z94P11	21/08/2020	FR0010259150	784	86,08	TRQX
IPSEN	549300M6SGDPB4Z94P11	21/08/2020	FR0010259150	531	86,07	BATE
			Total	11,614	86,26

The information detailed by transaction and the buy-back objectives are available on the company's website at the following address: http://www.ipsen.com/investors/regulated-information/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005067/en/

Latest news about Ipsen

Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
IPSEN : UBS reiterates its buy recommendation	Feb. 14	CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults	Feb. 13	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
Transcript : Ipsen S.A., 2023 Earnings Call, Feb 08, 2024	Feb. 08
Ipsen: 13% drop in annual EPS	Feb. 08	CF
Transcript : Ipsen S.A., 2023 Pre Recorded Earnings Call, Feb 08, 2024	Feb. 07
Ipsen presents positive data for Cabometyx	Jan. 23	CF
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024	Jan. 22	CI
IPSEN : Deutsche Bank lowers its target price	Dec. 15	CF
IPSEN : Ipsen outlined some promising mid-term takeaways at the CMD	Dec. 08
IPSEN : UBS remains Buy after CMD	Dec. 08	CF
Genfit: upbeat after updated outlook	Dec. 08	CF
Transcript : Ipsen S.A. - Analyst/Investor Day	Dec. 07

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Sales and Revenue Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Ipsen’s underlying fundamentals remain promising

March 13, 2024 at 11:50 am EDT

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

108.4 EUR

Average target price

124.6 EUR

Spread / Average Target

+14.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+0.46%	9.61B
ELI LILLY AND COMPANY	+28.79%	677B
NOVO NORDISK A/S	+25.94%	560B
JOHNSON & JOHNSON	-5.84%	355B
MERCK & CO., INC.	+15.75%	319B
ABBVIE INC.	+4.32%	287B
ASTRAZENECA PLC	+4.00%	214B
NOVARTIS AG	+1.92%	207B
ROCHE HOLDING AG	-7.93%	199B
PFIZER, INC.	-10.00%	146B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

IPSEN: Disclosure of Transactions in Own Shares Between 17/08/2020 and 21/08/2020

Latest news about Ipsen

Chart Ipsen

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Ipsen

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals